Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 19992008 and treated with curative intent in the AIDS Malignancy Consortium

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2383-2389

  Bayraktar, Ulas D ^a   Ramos, Juan Carlos ^a   Petrich, Adam ^b   Gupta, Neel ^c   Lensing, Shelly ^d   Moore, P C ^d   Reid, Erin G ^e   Aboulafia, David M ^f   Ratner, Lee ^g   Mitsuyasu, Ronald ^h   Cooley, Timothy ⁱ   Henry, David H ^j   Barr, Paul ^k   Noy, Ariela ^c  

^a UNIVERSITY OF MIAMI   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VIRGINIA MASON MEDICAL CENTER   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^j PENNSYLVANIA HOSPITAL   (United States)

^k CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Acquired immune deficiency syndrome; Lymphoma; Salvage therapy; Stem cell transplant

Indexed keywords

CARBOPLATIN; CD20 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACQUIRED IMMUNE DEFICIENCY SYNDROME RELATED LYMPHOMA; ADULT; ANEMIA; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LONG TERM SURVIVAL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4 LYMPHOCYTE COUNT; COMBINED MODALITY THERAPY; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAUSEA; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TRANSPLANTATION, AUTOLOGOUS; VOMITING; YOUNG ADULT;

EID: 84868379222     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.697559     Document Type: Article

References (28)

1. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-2344.
2. Engels EA, Goedert JJ. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future. J Natl Cancer Inst 2005;97:407-409. (Pubitemid 40528595)
3. Little RF. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-4659. (Pubitemid 36857717)
4. Tirelli U, Errante D, Spina M, et al. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Cancer 1996;77:2127-2131.
5. Kaplan LD, Moran T, Song L, et al. Continuous infusion ifosfamide/MESNA with daily etoposide for refractory HIV-associated non-Hodgkin's lymphoma. Presented at 1998 ASCO Annual Meeting (Los Angeles, CA). Abstract 185.
6. Levine AM, Tulpule A, Tessman D, et al. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. J Clin Oncol 1997;15:1094-1103. (Pubitemid 27106294)
7. Spina M, Vaccher E, Juzbasic S, et al. Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer 2001;92:200-206. (Pubitemid 32623058)
8. Bi J, Espina BM, Tulpule A, et al. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 2001;28:416-421. (Pubitemid 34033191)
9. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-1176. (Pubitemid 24173930)
10. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776-3785.
11. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
12. Molina A, Krishnan AY, Nademanee A, et al. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 2000;89:680-689. (Pubitemid 30640116)
13. Gabarre J, Azar N, Autran B, et al. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 2000;355:1071-1072. (Pubitemid 30162812)
14. Krishnan A, Palmer JM, Zaia JA, et al. HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant 2010;16:1302-1308.
15. Diez-Martin JL, Balsalobre P, Re A, et al. Comparable survival between HIV and HIV-non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 2009;113:6011-6014.
16. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009;114:1306-1313.
17. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-4190.
18. Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011;29:4079-4087.
19. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275-282. (Pubitemid 38029949)
20. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010;115:3008-3016.
21. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-4128. (Pubitemid 46622288)
22. Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92: 3562-3568. (Pubitemid 28525180)
23. Mounier N, Spina M, Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 2007;136:685-698.
24. Balsalobre P, Diez-Martin JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009;27:2192-2198.
25. Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23: 4430-4438. (Pubitemid 46207018)
26. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196-1205. (Pubitemid 37099904)
27. Noy A, Kaplan L, Lee J. Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL): preliminary results of a prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC). Blood 2009;114:1415-1416.
28. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94:1492-1499. (Pubitemid 34212643)